AzTrials
AzTrials

Femoral Artery StenosisLEVANT 2NCT01412541

Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Femoropopliteal Arteries

A study testing Standard Uncoated Angioplasty Balloon and Moxy Drug Coated Balloon in people with Femoral Artery Stenosis and Popliteal Artery Stenosis, run by C. R. Bard at 54 sites in 4 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of the study is to demonstrate the superior efficacy and non-inferior safety of the Moxy Drug Coated Balloon by direct comparison to standard percutaneous transluminal angioplasty (PTA) catheter for treatment of stenosis of the femoropopliteal arteries. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Standard Uncoated Angioplasty Balloon and Moxy Drug Coated Balloon
Could I receive a placebo?
No, everyone receives an active treatment
How many people
532 participants
Where
54 sitesin 4 countries
Study dates
Jul 2011to Dec 2018
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

None listed.

Who cannot join

  • Patients will be excluded if ANY of the following conditions apply:
  • Pregnant or planning on becoming pregnant or men intending to father children;
  • Life expectancy of <5 years;
  • Patient is currently participating in an investigational drug or other device study or previously enrolled in this study; NOTE: Enrollment in another clinical trial during the follow up period is not allowed.
  • History of hemorrhagic stroke within 3 months;
  • Previous or planned surgical or interventional procedure within 2 weeks before or within 30 days after the index procedure;
Show all 19Show fewer
  • History of myocardial infarction (MI), thrombolysis or angina within 2 weeks of enrollment;
  • Rutherford Class 0, 1, 5 or 6;
  • Renal failure or chronic kidney disease with modification in diet in renal disease glomerular filtration rate (MDRD GFR) ≤30 ml/min per 1.73 m2 (or serum creatinine ≥2.5 mg/L within 30 days of index procedure or treated with dialysis);
  • Prior vascular surgery of the index limb, with the exception of remote common femoral patch angioplasty separated by at least 2 cm from the target lesion;
  • Inability to take required study medications or allergy to contrast that cannot be adequately managed with pre- and post-procedure medication;
  • Anticipated use of IIb/IIIa inhibitor prior to randomization;
  • Ipsilateral retrograde access;
  • Composite lesion length is >15 cm or there is no normal proximal arterial segment in which duplex flow velocity can be measured;
  • Significant inflow disease. Successful treatment of inflow disease allowed prior to target lesion treatment;
  • Known inadequate distal outflow (>50 % stenosis of distal popliteal and/or all three tibial vessels), or planned future treatment of vascular disease distal to the target lesion;
  • Sudden symptom onset, acute vessel occlusion, or acute or sub-acute thrombus in target vessel;
  • Severe calcification that renders the lesion un-dilatable;
  • Use of adjunctive treatment modalities (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloon, etc.).

Trial locations and contacts

54 sites in 4 countries.

54 sites in 4 countries

United States42 sites
  • Austin Heart P.A.

    Austin, Texas, 78705

  • Massachusetts Genearl Hospital

    Boston, Massachusetts, 02114

  • Deborah Heart and Lung Center

    Browns Mills, New Jersey, 08015

  • Our Lady of Lourdes Medical Center

    Cherry Hill, New Jersey, 08034

  • Christ Hospital / The Lindner Clinical Trial Center

    Cincinnati, Ohio, 45219

  • Heart and Vascular Institute

    Clearwater, Florida, 33756

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44106

  • Cleveland Clinic

    Cleveland, Ohio, 44195

  • Mid Ohio Cardiology and Vascular Consultants

    Columbus, Ohio, 43214

  • Mercy Hosptial

    Coon Rapids, Minnesota, 55433

  • Methodist Medical Center

    Des Moines, Iowa, 50309

  • Detroit Medical Center

    Detroit, Michigan, 48201

  • St. John's Hospital

    Detroit, Michigan, 48236

  • Cardiovascular Associates

    Elk Grove Village, Illinois, 60007

  • Allen County Cardiology

    Fort Wayne, Indiana, 46802

  • Interventional Cardiolgists of Gainesville

    Gainesville, Florida, 32605

  • Greenville Memorial Hospital

    Greenville, South Carolina, 29615

  • Forrest General Hospital

    Hattiesburg, Mississippi, 39401

  • Promise Regional Medical Center

    Hutchinson, Kansas, 67502

  • St. Vincent Heart Center of Indianapolis

    Indianapolis, Indiana, 46260

  • Wellmont Cardiology Services

    Kingsport, Tennessee, 37660

  • East Tennessee Heart Consultants

    Knoxville, Tennessee, 37934

  • Good Samaritan Hospital

    Los Angeles, California, 90017

  • Medical Center of the Rockies

    Loveland, Colorado, 80538

  • Baptist DeSoto in Southaven

    Memphis, Tennessee, 38120

  • Yale New Haven Hospital

    New Haven, Connecticut, 06510

  • New York University Medical Center

    New York, New York, 10010

  • Mount Sinai Medical Center

    New York, New York, 10029

  • Columbia Universtiy Medical Center

    New York, New York, 10032

  • Advocate Christ Medical Center

    Oak Lawn, Illinois, 60453

  • Edward Heart

    Oakbrook Terrace, Illinois, 60181

  • Munroe Regional Medical Center

    Ocala, Florida, 34471

  • North County Radiology Medial Group Inc.

    Oceanside, California, 92056

  • St. Joseph's Hospital

    Orange, California, 92868

  • Wake Heart and Vascular

    Raleigh, North Carolina, 27610

  • University of California Davis

    Sacramento, California, 95817

  • St. John's Hospital

    Springfield, Illinois, 62701

  • Jobst Vascular Institute

    Toledo, Ohio, 43606

  • Univesrity of Toledo Medical Center

    Toledo, Ohio, 43614

  • St. Francis Heart & Vascular Center

    Topeka, Kansas, 66606

  • Washington Cardiology Center

    Washington D.C., District of Columbia, 20010

  • Michigan Heart

    Ypsilanti, Michigan, 48197

Other trials in United States

Germany8 sites
  • Herz-Zentrum

    Bad Krozingen, 79189

  • Jewish Hospital

    Berlin, 13347

  • Universitätsklinikum Carl Gustav Carus

    Dresden, 01307

  • Diakonissenanstalt zu Flensburg

    Flensburg, 24939

  • Hamburg University Cardiovascular Center

    Hamburg, 22527

  • University Leipzig

    Leipzig, 04103

  • University Magdeburg

    Magdeburg, 39120

  • University of Tübingen

    Tübingen, 72076

Other trials in Germany

Austria2 sites
  • Medical University of Graz

    Graz, A-8036

  • Medical University of Vienna

    Vienna, 1090

Other trials in Austria

Belgium2 sites
  • Imelda Ziekenhuis

    Bonheiden, 2820

  • Flanders Medical Research Program

    Dendermonde, 9200

Other trials in Belgium

About this study

Official title: A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal Arteries

The purpose of the study is to demonstrate the superior efficacy and non-inferior safety of the Moxy Drug Coated Balloon by direct comparison to standard percutaneous transluminal angioplasty (PTA) catheter for treatment of stenosis of the femoropopliteal arteries.

Read the detailed description

The Moxy Drug Coated Balloon is indicated for percutaneous transluminal angioplasty of obstructive de novo or non-stented restenotic lesions in native femoropopliteal arteries up to 15 cm in length and ≥4.0 to ≤6.0 mm in diameter. This study will randomize approximately 476 patients who will receive either the Moxy balloon or standard balloon angioplasty at 55 global investigational sites. Subjects will be blinded to treatment until 12 months and will participate in long term follow-up for 5 years.

Being tested
Standard Uncoated Angioplasty Balloon, Moxy Drug Coated Balloon
Keywords
Arms, Experimental, Drug Coated Angioplasty Balloon, Active Comparator, Standard Angioplasty Balloon
Medical subject headings
Rhabdomyosarcoma, Alveolar

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Standard Uncoated Angioplasty BalloonProcedure or surgery

    Subjects will be randomized 2:1 to the Moxy Drug Coated Balloon or Standard Angioplasty Balloon

  • Moxy Drug Coated BalloonDevice

    Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon

Study groups in NCT01412541
Study groupRoleWhat they receive
Moxy Drug Coated BalloonExperimentalPaclitaxel coated balloon catheter
Receives: Device: Moxy Drug Coated Balloon
Standard Uncoated Angioplasty BalloonActive comparatorPTA Catheter
Receives: Procedure: Standard Uncoated Angioplasty Balloon

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants With Composite Freedom From All-Cause Peri-Operative (≤30 Day) Death and Freedom From Index Limb Amputation, Index Limb Re-Intervention, and Index-Limb-Related Death at 12 Months Post Index Procedure

    Composite of freedom from all-cause peri-operative (≤30 day) death and freedom at 1 year from the following: index limb amputation (above or below the ankle), index limb re-intervention, and index-limb-related death.

    Measured: 12 months post index procedure

  2. Percentage of Participants With Primary Patency of the Target Lesion at 12 Months Post Index Procedure

    Primary Patency is defined as the absence of target lesion restenosis (defined by DUS peak systolic velocity ratio (PSVR) ≥2.5) and freedom from target lesion revascularization (TLR).

    Measured: 12 months post index procedure

Secondary outcomes (16)
  1. Number of Acute Device Success at Time of Index Procedure

    Device Success was defined as the achievement of successful delivery and deployment of the study device(s) as intended at the intended target lesion, without balloon rupture or inflation/deflation abnormalities and a successful withdrawal of the study system.

    Measured: At time of Index Procedure

  2. Number of Participants With Technical and Procedural Success

    Technical Success is defined as successful access and deployment of the device and visual estimate of ≤30% diameter residual stenosis during the index procedure without deployment of a bailout stent.

    Procedural Success is defined as attainment of ≤30% residual stenosis in the treatment area by independent core lab analysis without serious adverse events during the index procedure.

    Measured: At time of Index Procedure

  3. Number of Participants With Primary Patency at 6, 12, and 24 Months Post Index Procedure

    Primary Patency is defined as the absence of target lesion restenosis (defined by core lab adjudication or strict application of PSVR thresholds) and freedom from target lesion revascularization (TLR).

    Measured: 6, 12, and 24 months post index procedure

  4. Number of Participants With Alternative Primary Patency at 6, 12, and 24 Months Post Index Procedure

    Percentage of subjects with Alternative Primary Patency based on alternative definitions of duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) <2.0 and <3.0 at 6, 12, and 24 months post index procedure. DUS PSVR was calculated by dividing the maximum peak systolic velocity (PSV) from the stenosis by the PSV from the nearest segment of normal artery above the site of increase.

    Measured: 6, 12, and 24 months post index procedure

  5. Number of Participants With Duplex Ultrasound (DUS) Clinical Patency at 6, 12, and 24 Months Post Index Procedure

    DUS Clinical Patency defined as DUS PSVR <2.5 without prior clinically driven target lesion revascularization (TLR).

    Measured: 6, 12, and 24 months post index porcedure

  6. Number of Participants With Freedom From Target Lesion Revascularization (TLR) Clinically-driven at 6, 12, and 24 Months Post Index Procedure

    Measured: 6, 12, and 24 months post index procedure

  7. Improvement in Rutherford Classification Scores at 6, 12, and 24 Months Post Index Procedure Compared to Baseline

    The endpoint summarizes the change in index-limb Rutherford Classification of participants from baseline through 24 months. Data is presented as shift from baseline Rutherford Classification data using the following categories: 1) Improvement, 2) Same, and 3) Worsened.

    Measured: 6, 12, and 24 months post index procedure

  8. Change in Resting Ankle Brachial Index (ABI) at 6, 12, and 24 Months Compared to Baseline

    Mean change from baseline values. The Ankle Brachial Index (ABI) is defined as a ratio of ankle to brachial (upper arm) artery systolic blood pressure and aims at determining how well the blood is flowing in the legs.

    Measured: 6, 12, and 24 months from baseline

  9. Change in Six Minute Walk Test Distance at 6, 12, and 24 Months Compared to Baseline

    The data bellow is presented as a Mean change in scores for the Six Minute Walk Test scores at 6, 12, and 24 months compared to baseline.

    Measured: 6, 12, and 24 months from baseline

  10. Change in European Quality of Life 5 Dimensions (EuroQol -5D) Scores at 6, 12, and 24 Months Compared to Baseline.

    Mean change in EuroQol (EQ-5D) scores at 6, 12, and 24 months compared to baseline. The EurolQol-5D system rates quality of life using five dimensions including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels of ratings, that is, no problems, slight problems, moderate problems, severe problems and extreme problems that can be selected. A visual scale allows participants to report their own perception of their health status. The overall scores range from 0 (worst) to 100 (best). Please note that the data in the table below represent the mean changes in overall scores for each group compared to their baseline data.

    Measured: 6, 12, and 24 months

  11. Change in Score on the Short Form Quality of Life Measure (Physical Component) at 6, 12, and 24 Months Compared to Baseline.

    Mean change from Baseline on the Short Form (SF-36 v2) Quality of Life Questionnaire at 6, 12, and 24 months. The SF-36 v2 United States (US) is a brief measure of general health status. The physical health measure of the test comprises four scales, that is, physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The scores range between 0 and 100 (with higher scores indicating better health). In the results presented below, a positive Mean represents an increase in the average health score while a negative Mean represents a decrease in the same mean score compared to baseline measure.

    Measured: 6, 12, and 24 months

  12. Change in Quality of Life (Mental Component) on the Short-form 36 (SF-36 v2) at 6, 12, and 24 Months Compared to Baseline

    Mean change in quality of life (mental component) on Short-form 36 (SF-36 v2) from baseline at 6, 12, and 24 months. The SF-36 v2 United States (US) is a brief measure of general health status. The mental health measure comprises four scales, that is, vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). The scores range from 0 to 100 (with higher scores indicating better health). In the results presented below, a positive Mean represents an increase in the average health score while a negative Mean represents a decrease in the same mean score compared to baseline measure.

    Measured: 6, 12, and 24 months from baseline

  13. Number of Subjects With Freedom From Death, Index-Limb Amputation, and Target Vessel Revascularization (TVR) at 30 Days Post Index Porcedure

    Number of subjects with Freedom from all-cause death, index limb amputation above the ankle and Target Vessel Revascularization (TVR) (VIVA Safety Endpoint)

    Measured: 30 days post index procedure

  14. Number of Participants With Composite of Freedom From All-Cause Perioperative (<30 Day) Death and Freedom From the Following at 1,6, 24, 36, 48, and 60 Months: Index Limb Amputation, Index Limb Re-intervention, and Index Limb Related Death

    Measured: 1, 6, 24, 36, 48, and 60 months post index procedure

  15. Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.

    Amputation defined as above the ankle free survival (AFS). PPI = Post index procedure.

    Measured: 1, 6, 12, 24, 36, 48, and 60 months post index procedure

  16. Change in Walking Impairment Questionnaire (WIQ) Scores at 6, 12, and 24 Months Post Index Procedure Compared to Baseline.

    The WIQ assesses 3 categories of activities that include 1) walking distance, 2) stair-climbing, and 3) walking speed. Each question requires participants to rate their degree of difficulty with the activity on a scale of 0 (unable) to 4 (no problem). Final scores range from 0% to 100%, with lower percentages indicating higher levels of difficulties with activities.The results below represent the mean differences in total Walking Impairment Questionnaire (WIQ) scores at 6, 12, and 24 months, compared to baseline assessment scores.

    Measured: 6, 12, and 24 months post index procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Aug 2011 (estimated)
  2. Study startJul 2011
  3. Primary completionNov 2013
  4. Study completionDec 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
532 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01412541
Sponsor's protocol ID
CL0002-01
Acronym
LEVANT 2
Status last verified
May 2020
First submitted
5 Aug 2011
Last updated
12 May 2020
Data monitoring committee
Yes

Publications

  • Ma GW, Bernatchez J, Yarranton B, Dueck AD, Rajan DK, Forbes TL, de Mestral C, Kayssi A. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs. Cochrane Database Syst Rev. 2026 Aug 10;8:CD011319. doi: 10.1002/14651858.CD011319.pub3.

    PubMed 42573020
  • Ouriel K, Adelman MA, Rosenfield K, Scheinert D, Brodmann M, Pena C, Geraghty P, Lee A, White R, Clair DG. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease. JACC Cardiovasc Interv. 2019 Dec 23;12(24):2515-2524. doi: 10.1016/j.jcin.2019.08.025. Epub 2019 Sep 28.

    PubMed 31575518
  • Scheinert D, Schmidt A, Zeller T, Muller-Hulsbeck S, Sixt S, Schroder H, Weiss N, Ketelsen D, Ricke J, Steiner S, Rosenfield K. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease. J Endovasc Ther. 2016 Jun;23(3):409-16. doi: 10.1177/1526602816644592. Epub 2016 Apr 26.

    PubMed 27117972
  • Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, Brodmann M, Pilger E, Zeller T, Krishnan P, Gammon R, Muller-Hulsbeck S, Nehler MR, Benenati JF, Scheinert D; LEVANT 2 Investigators. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. N Engl J Med. 2015 Jul 9;373(2):145-53. doi: 10.1056/NEJMoa1406235. Epub 2015 Jun 24.

    PubMed 26106946

Questions about this trial

What is this clinical trial studying?

A study testing Standard Uncoated Angioplasty Balloon and Moxy Drug Coated Balloon in people with Femoral Artery Stenosis and Popliteal Artery Stenosis, run by C. R. Bard at 54 sites in 4 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 0 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 May 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 54 sites in United States, Germany, Austria, Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 29 Mar 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants With Composite Freedom From All-Cause Peri-Operative (≤30 Day) Death and Freedom From Index Limb Amputation, Index Limb Re-Intervention, and Index-Limb-Related Death at 12 Months Post Index Procedure (time frame: 12 months post index procedure). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01412541, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 May 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in